CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
hI-con1™ 60µl +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01485588
NCT01485588Phase 2Completed
CompareCT.gov

A Phase 1 / 2 Trial to Investigate The Safety and Tolerability of Single and Repeated Doses of hI-CON1™ Following Administration by Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Iconic Therapeutics, Inc.·interventional·Posted Dec 5, 2011·Updated Nov 6, 2020

In Brief

A Phase 2 clinical trial evaluating hI-con1™ 60µl, hI-con1™ 150µl, and 1 other intervention for Neovascular Age-Related Macular Degeneration. Completed, enrolled 18 participants across 5 sites.

Detailed Summary

Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-Related Macular Degeneration
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2011
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.6 years ago

Interventions

hI-con1™ 60µldrug

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

hI-con1™ 150µldrug

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

hI-con1™ 300µldrug

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only